
UC Davis Health’s Tiffany Phung, Pharm.D., and Tim Cutler, Pharm.D., say staff-driven ideas protect research independence in industry partnerships.
Biosimilars generally enter the market priced at roughly 50% of the amount of their reference drugs.
With eight new biosimilars approved by midpoint 2024, these lower-cost biologics are one of the few deflationary factors in an otherwise relentlessly upward trend of medical cost inflation.






